Pre-clinical research has demonstrated that Akt can activate the estrogen receptor (ER) pathway regardless of the availability of estrogen and that mTOR inhibitors in conjunction with endocrine therapy can overcome resistance to endocrine therapy in BC that is HR+. This evidence concerns the gene AKT1 and breast cancer.